-
1
-
-
22044442973
-
Tyrosine kinases as targets for cancer therapy
-
16014887 1:CAS:528:DC%2BD2MXmtFClsbs%3D 10.1056/NEJMra044389
-
Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187
-
(2005)
N Engl J Med
, vol.353
, pp. 172-187
-
-
Krause, D.S.1
Van Etten, R.A.2
-
2
-
-
78651156947
-
Experimental evaluation of potential anticancer agents. XIII. on the criteria and kinetics associated with "curability" of experimental leukemia
-
14117037 1:CAS:528:DyaF2cXnvVaitw%3D%3D
-
Skipper HE, Schabel FM, Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35:1-111
-
(1964)
Cancer Chemother Rep
, vol.35
, pp. 1-111
-
-
Skipper, H.E.1
Schabel, F.M.2
Wilcox, W.S.3
-
3
-
-
0035214416
-
Metronomic scheduling: The future of chemotherapy?
-
11902515 1:CAS:528:DC%2BD38XjvVKluw%3D%3D 10.1016/S1470-2045(01)00587-3
-
Gasparini G (2001) Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2:733-740
-
(2001)
Lancet Oncol
, vol.2
, pp. 733-740
-
-
Gasparini, G.1
-
4
-
-
0034032882
-
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
-
Browder T, Butterfield CE, Kräling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 7:1878-1886
-
(2000)
Cancer Res
, vol.7
, pp. 1878-1886
-
-
Browder, T.1
Butterfield, C.E.2
Kräling, B.M.3
-
5
-
-
2942615257
-
The anti-angiogenic basis of metronomic chemotherapy
-
15170445 1:CAS:528:DC%2BD2cXksVaisbk%3D 10.1038/nrc1369
-
Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 423-436
-
-
Kerbel, R.S.1
Kamen, B.A.2
-
6
-
-
0034087691
-
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity
-
10772661 1:CAS:528:DC%2BD3cXisFOlurc%3D 10.1172/JCI8829
-
Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J Clin Invest 105:R15-R24
-
(2000)
J Clin Invest
, vol.105
-
-
Klement, G.1
Baruchel, S.2
Rak, J.3
-
7
-
-
0034048358
-
Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice
-
10772648 1:CAS:528:DC%2BD3cXisFOltbg%3D 10.1172/JCI9872
-
Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J Clin Invest 105:1045-1047
-
(2000)
J Clin Invest
, vol.105
, pp. 1045-1047
-
-
Hanahan, D.1
Bergers, G.2
Bergsland, E.3
-
8
-
-
0034243694
-
High-Time chemotherapy or high time for low dose
-
10944125 1:STN:280:DC%2BD3cvivFCltA%3D%3D
-
Kamen BA, Rubin E, Aisner J et al (2000) High-Time chemotherapy or high time for low dose. J Clin Oncol 18:2935-2937
-
(2000)
J Clin Oncol
, vol.18
, pp. 2935-2937
-
-
Kamen, B.A.1
Rubin, E.2
Aisner, J.3
-
9
-
-
0025743487
-
Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC breast cancer co-operative group phase III trial (10808)
-
1832904 1:STN:280:DyaK38%2FgtVyrsQ%3D%3D 10.1016/0277-5379(91)90259-G
-
Engelsman E, Klijn JC, Rubens RD et al (1991) "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC breast cancer co-operative group phase III trial (10808). Eur J Cancer 27:966-970
-
(1991)
Eur J Cancer
, vol.27
, pp. 966-970
-
-
Engelsman, E.1
Klijn, J.C.2
Rubens, R.D.3
-
10
-
-
0031753296
-
Treatment of non-small-cell lung cancer with prolonged oral etoposide
-
9781610 1:STN:280:DyaK1cvlt1yksg%3D%3D 10.1097/00000421-199810000-00018
-
Kakolyris S, Samonis G, Koukourakis M et al (1998) Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol 21:505-508
-
(1998)
Am J Clin Oncol
, vol.21
, pp. 505-508
-
-
Kakolyris, S.1
Samonis, G.2
Koukourakis, M.3
-
11
-
-
0031041147
-
Dose intensity for bolus versus infusion chemotherapy administration: Review of the literature for 27 anti-neoplastic agents
-
9093703 1:STN:280:DyaK2s3kslGktA%3D%3D 10.1023/A:1008243806415
-
Lokich J, Anderson N (1997) Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. Ann Oncol 8:15-25
-
(1997)
Ann Oncol
, vol.8
, pp. 15-25
-
-
Lokich, J.1
Anderson, N.2
-
12
-
-
0031757277
-
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
-
9779712 1:CAS:528:DyaK1cXmvFGrtbY%3D
-
Seidman AD, Hudis CA, Albanel J et al (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361
-
(1998)
J Clin Oncol
, vol.16
, pp. 3353-3361
-
-
Seidman, A.D.1
Hudis, C.A.2
Albanel, J.3
-
13
-
-
0034061842
-
Docetaxel administered on a weekly basis for metastatic breast cancer
-
10715290 1:CAS:528:DC%2BD3cXit12lt7k%3D
-
Burstein HJ, Manola J, Younger J et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212-1219
-
(2000)
J Clin Oncol
, vol.18
, pp. 1212-1219
-
-
Burstein, H.J.1
Manola, J.2
Younger, J.3
-
15
-
-
24944542869
-
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 week
-
1:CAS:528:DC%2BD2MXhtVKgtb3O 10.1200/JCO.2005.06.232
-
Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 week. JCO 23:5983-5992
-
(2005)
JCO
, vol.23
, pp. 5983-5992
-
-
Green, M.C.1
Buzdar, A.U.2
Smith, T.3
-
16
-
-
42249083269
-
Weekly paclitaxel in the adjuvant treatment of breast cancer
-
18420499 1:CAS:528:DC%2BD1cXkslCitLk%3D 10.1056/NEJMoa0707056
-
Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663-1671
-
(2008)
N Engl J Med
, vol.358
, pp. 1663-1671
-
-
Sparano, J.A.1
Wang, M.2
Martino, S.3
-
17
-
-
14644446018
-
A multitargeted, metronomic, and maximum-tolerated dose ''chemo-switch'' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
-
15557593 1:CAS:528:DC%2BD2MXit1Ggu7k%3D 10.1200/JCO.2005.07.093
-
Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose ''chemo-switch'' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939-952
-
(2005)
J Clin Oncol
, vol.23
, pp. 939-952
-
-
Pietras, K.1
Hanahan, D.2
-
18
-
-
77955172181
-
Metronomic chemotherapy: New rationale for new directions
-
20531380 10.1038/nrclinonc.2010.82
-
Pasquier E, Kavallaris M, André N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455-465
-
(2010)
Nat Rev Clin Oncol
, vol.7
, pp. 455-465
-
-
Pasquier, E.1
Kavallaris, M.2
André, N.3
-
19
-
-
0035865363
-
Redefining the target: Chemotherapeutics as antiangiogenics
-
11181686 1:CAS:528:DC%2BD3MXhvFertrY%3D
-
Miller KD, Sweeney CJ, Sledge GW (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195-1206
-
(2001)
J Clin Oncol
, vol.19
, pp. 1195-1206
-
-
Miller, K.D.1
Sweeney, C.J.2
Sledge, G.W.3
-
20
-
-
60549092506
-
Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
-
19168635 1:CAS:528:DC%2BD1MXit1yqtLg%3D 10.1073/pnas.0812801106
-
Lee KA, Qian DZ, Rey S et al (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci 106:2353-2358
-
(2009)
Proc Natl Acad Sci
, vol.106
, pp. 2353-2358
-
-
Lee, K.A.1
Qian, D.Z.2
Rey, S.3
-
21
-
-
84868207640
-
Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α
-
22684860 1:CAS:528:DC%2BC38XptVyis7c%3D 10.1002/ijc.27666
-
Kim YJ, Lee HJ, Kim TM et al (2013) Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α. Int J Cancer 132:29-41
-
(2013)
Int J Cancer
, vol.132
, pp. 29-41
-
-
Kim, Y.J.1
Lee, H.J.2
Kim, T.M.3
-
22
-
-
79953159535
-
Metronomic scheduling of anticancer treatments: The next generation of multi target therapy?
-
21417902 10.2217/fon.11.11
-
André N, Padovani L, Pasquier E (2011) Metronomic scheduling of anticancer treatments: the next generation of multi target therapy? Future Oncol 7:385-394
-
(2011)
Future Oncol
, vol.7
, pp. 385-394
-
-
André, N.1
Padovani, L.2
Pasquier, E.3
-
23
-
-
16844385404
-
Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen stimulated phenotype in athymic mice
-
15781616 1:CAS:528:DC%2BD2MXisFGgtbk%3D 10.1158/0008-5472.CAN-04-3992
-
Chuu CP, Hiipakka RA, Fukuchi J et al (2005) Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen stimulated phenotype in athymic mice. Cancer Res 65:2082-2084
-
(2005)
Cancer Res
, vol.65
, pp. 2082-2084
-
-
Chuu, C.P.1
Hiipakka, R.A.2
Fukuchi, J.3
-
24
-
-
41849122758
-
Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors
-
17941070 10.1002/pbc.21381
-
Choi LM, Rood B, Kamani N et al (2008) Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer 50:970-975
-
(2008)
Pediatr Blood Cancer
, vol.50
, pp. 970-975
-
-
Choi, L.M.1
Rood, B.2
Kamani, N.3
-
25
-
-
84863883498
-
Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors
-
22147459 10.1002/pbc.24006
-
Peyrl A, Chocholous M, Kieran MW et al (2012) Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 59:511-517
-
(2012)
Pediatr Blood Cancer
, vol.59
, pp. 511-517
-
-
Peyrl, A.1
Chocholous, M.2
Kieran, M.W.3
-
26
-
-
33745635043
-
The stem-cell niche as an entity of action
-
16810242 1:CAS:528:DC%2BD28XmtlahsrY%3D 10.1038/nature04957
-
Scadden DT (2006) The stem-cell niche as an entity of action. Nature 441:1075-1079
-
(2006)
Nature
, vol.441
, pp. 1075-1079
-
-
Scadden, D.T.1
-
27
-
-
33846029123
-
A perivascular niche for brain tumor stem cells
-
17222791 1:CAS:528:DC%2BD2sXhtFClsLY%3D 10.1016/j.ccr.2006.11.020
-
Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82
-
(2007)
Cancer Cell
, vol.11
, pp. 69-82
-
-
Calabrese, C.1
Poppleton, H.2
Kocak, M.3
-
28
-
-
34248550985
-
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
-
17440065 1:CAS:528:DC%2BD2sXkt1Kju70%3D 10.1158/0008-5472.CAN-06-4238
-
Folkins C, Man S, Xu P et al (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560-3564
-
(2007)
Cancer Res
, vol.67
, pp. 3560-3564
-
-
Folkins, C.1
Man, S.2
Xu, P.3
-
29
-
-
20044366163
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
-
15758009 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330
-
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996
-
(2005)
N Engl J Med
, vol.352
, pp. 987-996
-
-
Stupp, R.1
Mason, W.P.2
Van Den Bent, M.J.3
-
30
-
-
0032767387
-
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
-
10561324 1:STN:280:DC%2BD3c%2FjtVSmsQ%3D%3D
-
Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
-
(1999)
J Clin Oncol
, vol.17
, pp. 2572-2578
-
-
Wong, E.T.1
Hess, K.R.2
Gleason, M.J.3
-
31
-
-
0042833109
-
Inhibition of angiogenesis by non-toxic doses of temozolomide
-
12960735 1:CAS:528:DC%2BD3sXmvF2itr0%3D 10.1097/00001813-200308000-00003
-
Kurzen H, Schmitt S, Naher H et al (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14:515-522
-
(2003)
Anticancer Drugs
, vol.14
, pp. 515-522
-
-
Kurzen, H.1
Schmitt, S.2
Naher, H.3
-
32
-
-
11244315274
-
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme
-
15565458 1:CAS:528:DC%2BD2cXhtVWjt7zN 10.1007/s00432-004-0620-5
-
Tuettenberg J, Grobholz R, Korn T et al (2005) Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131:31-40
-
(2005)
J Cancer Res Clin Oncol
, vol.131
, pp. 31-40
-
-
Tuettenberg, J.1
Grobholz, R.2
Korn, T.3
-
33
-
-
0030053959
-
Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma
-
8699237 1:STN:280:DyaK283jsVOlug%3D%3D 10.1007/BF00177478
-
Fulton D, Urtasun R, Forsyth P (1996) Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27:149-155
-
(1996)
J Neurooncol
, vol.27
, pp. 149-155
-
-
Fulton, D.1
Urtasun, R.2
Forsyth, P.3
-
34
-
-
14944379060
-
UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma
-
15735920 1:CAS:528:DC%2BD28XksQ%3D%3D 10.1007/s11060-004-1726-y
-
Herrlinger U, Rieger J, Steinbach JP et al (2005) UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol 71:295-299
-
(2005)
J Neurooncol
, vol.71
, pp. 295-299
-
-
Herrlinger, U.1
Rieger, J.2
Steinbach, J.P.3
-
35
-
-
34547486126
-
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
-
17452651 1:CAS:528:DC%2BD2sXpt1agtrY%3D 10.1215/15228517-2007-006
-
Kesari S, Schiff D, Doherty L et al (2007) Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9:354-363
-
(2007)
Neuro Oncol
, vol.9
, pp. 354-363
-
-
Kesari, S.1
Schiff, D.2
Doherty, L.3
-
36
-
-
71649094684
-
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A phase II study
-
19920819 1:CAS:528:DC%2BD1MXhsFaqtr7L 10.1038/sj.bjc.6605412
-
Reardon DA, Desjardins A, Vredenburgh JJ et al (2009) Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101:1986-1994
-
(2009)
Br J Cancer
, vol.101
, pp. 1986-1994
-
-
Reardon, D.A.1
Desjardins, A.2
Vredenburgh, J.J.3
-
37
-
-
77952311482
-
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
-
20167817 1:CAS:528:DC%2BC3cXot1Gmurg%3D 10.1093/neuonc/nop030
-
Kong DS, Lee JI, Kim JH et al (2010) Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol 12:289-296
-
(2010)
Neuro Oncol
, vol.12
, pp. 289-296
-
-
Kong, D.S.1
Lee, J.I.2
Kim, J.H.3
-
38
-
-
77951648272
-
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study
-
20308655 1:CAS:528:DC%2BC3cXmtlSksrk%3D 10.1200/JCO.2009.26.5520
-
Perry JR, Bélanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051-2057
-
(2010)
J Clin Oncol
, vol.28
, pp. 2051-2057
-
-
Perry, J.R.1
Bélanger, K.2
Mason, W.P.3
-
39
-
-
78449288666
-
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
-
20446016 1:CAS:528:DC%2BC3cXhtlant77F 10.1007/s11060-010-0192-y
-
Stockhammer F, Misch M, Koch A et al (2010) Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. J Neurooncol 100:407-415
-
(2010)
J Neurooncol
, vol.100
, pp. 407-415
-
-
Stockhammer, F.1
Misch, M.2
Koch, A.3
-
40
-
-
36049037819
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
-
17947719 1:CAS:528:DC%2BD2sXhtlCgsLjF 10.1200/JCO.2007.12.2440
-
Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729
-
(2007)
J Clin Oncol
, vol.25
, pp. 4722-4729
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Herndon II, J.E.3
-
41
-
-
79959812904
-
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
-
20853132 1:CAS:528:DC%2BC3MXmtl2ntrw%3D 10.1007/s11060-010-0403-6
-
Reardon DA, Desjardins A, Peters K et al (2011) Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 103:371-379
-
(2011)
J Neurooncol
, vol.103
, pp. 371-379
-
-
Reardon, D.A.1
Desjardins, A.2
Peters, K.3
-
42
-
-
84857373272
-
Bevacizumab and daily temozolomide for recurrent glioblastoma
-
21792866 1:CAS:528:DC%2BC38XisVyhsr4%3D 10.1002/cncr.26381
-
Desjardins A, Reardon DA, Coan A et al (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302-1312
-
(2012)
Cancer
, vol.118
, pp. 1302-1312
-
-
Desjardins, A.1
Reardon, D.A.2
Coan, A.3
-
43
-
-
70350461699
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
-
19720927 1:CAS:528:DC%2BD1MXhtlGgtbbM 10.1200/JCO.2008.19.8721
-
Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740
-
(2009)
J Clin Oncol
, vol.27
, pp. 4733-4740
-
-
Friedman, H.S.1
Prados, M.D.2
Wen, P.Y.3
-
44
-
-
68949085460
-
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma
-
19506159 1:CAS:528:DC%2BD1MXhtFaitrrJ 10.1200/JCO.2008.20.7944
-
Clarke JL, Iwamoto FM, Sul J et al (2009) Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 27:3861-3867
-
(2009)
J Clin Oncol
, vol.27
, pp. 3861-3867
-
-
Clarke, J.L.1
Iwamoto, F.M.2
Sul, J.3
-
45
-
-
33745783111
-
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: Single-center pilot study
-
16874014 1:CAS:528:DC%2BD28XnsVygsrw%3D 10.1159/000093474
-
Sterba J, Valik D, Mudry P et al (2006) Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 29:308-313
-
(2006)
Onkologie
, vol.29
, pp. 308-313
-
-
Sterba, J.1
Valik, D.2
Mudry, P.3
-
46
-
-
78649651498
-
A phase II study of metronomic oral topotecan for recurrent childhood brain tumors
-
21108437 10.1002/pbc.22690
-
Janss AJ, Minturn JE, Fisher PG et al (2011) A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer 56:39-44
-
(2011)
Pediatr Blood Cancer
, vol.56
, pp. 39-44
-
-
Janss, A.J.1
Minturn, J.E.2
Fisher, P.G.3
-
47
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
11248153 1:CAS:528:DC%2BD3MXisVGktrc%3D 10.1056/NEJM200103153441101
-
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
48
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
18160686 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 10.1056/NEJMoa072113
-
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
49
-
-
77954700380
-
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
-
20498403 1:CAS:528:DC%2BC3cXhtVajur3P 10.1200/JCO.2008.21.6457
-
Miles DW, Chan A, Dirix LY (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247
-
(2010)
J Clin Oncol
, vol.28
, pp. 3239-3247
-
-
Miles, D.W.1
Chan, A.2
Dirix, L.Y.3
-
50
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
17192538 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D 10.1056/NEJMoa064320
-
Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743
-
(2006)
N Engl J Med
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
-
51
-
-
36849071808
-
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
-
17968020 1:CAS:528:DC%2BD2sXhsVKnsbzO 10.1200/JCO.2007.12.6557
-
Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217
-
(2007)
J Clin Oncol
, vol.25
, pp. 5210-5217
-
-
Thomas, E.S.1
Gomez, H.L.2
Li, R.K.3
-
52
-
-
84860815596
-
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome
-
21915801 1:CAS:528:DC%2BC38XivFOqtLk%3D 10.1007/s00262-011-1106-3
-
Ge Y, Domschke C, Stoiber N et al (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61:353-362
-
(2012)
Cancer Immunol Immunother
, vol.61
, pp. 353-362
-
-
Ge, Y.1
Domschke, C.2
Stoiber, N.3
-
53
-
-
0036225350
-
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumour activity and correlation with vascular endothelial growth factor levels
-
11863115 1:STN:280:DC%2BD387islyksw%3D%3D 10.1093/annonc/mdf013
-
Colleoni M, Rocca A, Sandri MTM et al (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumour activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13:73-80
-
(2002)
Ann Oncol
, vol.13
, pp. 73-80
-
-
Colleoni, M.1
Rocca, A.2
Sandri, M.T.M.3
-
54
-
-
84858289650
-
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy
-
10.1097/CAD.0b013e32834e735a 1:CAS:528:DC%2BC38XjtFaqsb0%3D
-
Miscoria M, Tonetto F, Deroma L et al (2011) Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy. Anticancer Drugs 23:326-334
-
(2011)
Anticancer Drugs
, vol.23
, pp. 326-334
-
-
Miscoria, M.1
Tonetto, F.2
Deroma, L.3
-
55
-
-
84856933036
-
Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma
-
22287742 1:CAS:528:DC%2BC38XjsF2lurs%3D
-
Gebbia V, Boussen H, Valerio MR et al (2012) Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. Anticancer Res 32:529-536
-
(2012)
Anticancer Res
, vol.32
, pp. 529-536
-
-
Gebbia, V.1
Boussen, H.2
Valerio, M.R.3
-
56
-
-
31544441697
-
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: Antitumour activity and biological effects
-
16322118 1:STN:280:DC%2BD28%2FjvVGksQ%3D%3D 10.1093/annonc/mdj066
-
Colleoni M, Orlando L, Sanna G et al (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumour activity and biological effects. Ann Oncol 17:232-238
-
(2006)
Ann Oncol
, vol.17
, pp. 232-238
-
-
Colleoni, M.1
Orlando, L.2
Sanna, G.3
-
57
-
-
77649221837
-
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response
-
20026801 1:CAS:528:DC%2BC3cXksVyrsbk%3D 10.1200/JCO.2009.24.0143
-
Wong NS, Buckman RA, Clemons M et al (2010) Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol 28:723-730
-
(2010)
J Clin Oncol
, vol.28
, pp. 723-730
-
-
Wong, N.S.1
Buckman, R.A.2
Clemons, M.3
-
58
-
-
79958113019
-
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
-
21587257 1:CAS:528:DC%2BC3MXntV2hsbY%3D 10.1038/bjc.2011.154
-
Khan OA, Blann AD, Payne MJ et al (2011) Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer 104:1822-1827
-
(2011)
Br J Cancer
, vol.104
, pp. 1822-1827
-
-
Khan, O.A.1
Blann, A.D.2
Payne, M.J.3
-
59
-
-
33749416983
-
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
-
16978400 10.1186/1471-2407-6-225 1:CAS:528:DC%2BD28XhtVequ7nI
-
Orlando L, Cardillo A, Ghisini R et al (2006) Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 6:225
-
(2006)
BMC Cancer
, vol.6
, pp. 225
-
-
Orlando, L.1
Cardillo, A.2
Ghisini, R.3
-
60
-
-
70449673266
-
Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer
-
19671111 10.1111/j.1524-4741.2009.00783.x
-
Gonzalez-Billalabeitia E, Calzas J, Castellano D et al (2009) Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer. Breast J 15:551-553
-
(2009)
Breast J
, vol.15
, pp. 551-553
-
-
Gonzalez-Billalabeitia, E.1
Calzas, J.2
Castellano, D.3
-
61
-
-
79960616984
-
Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
-
21397505 10.1016/j.breast.2011.02.014
-
Dellapasqua S, Mazza M, Colleoni M et al (2011) Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 20:319-323
-
(2011)
Breast
, vol.20
, pp. 319-323
-
-
Dellapasqua, S.1
Mazza, M.2
Colleoni, M.3
-
62
-
-
84856714423
-
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: A phase II study
-
21874317 1:CAS:528:DC%2BC38XhsVOktbs%3D 10.1007/s00280-011-1728-3
-
Wang Z, Lu J, Leaw S, Hong X et al (2012) An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 69:515-522
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 515-522
-
-
Wang, Z.1
Lu, J.2
Leaw, S.3
Hong, X.4
-
63
-
-
84866553726
-
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: A phase II study in patients with HER2-negative metastatic breast cancer
-
22526409 1:CAS:528:DC%2BC38XhtFWhsbrL 10.1007/s00280-012-1826-x
-
Yoshimoto M, Takao S, Hirata M et al (2012) Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol 70:331-338
-
(2012)
Cancer Chemother Pharmacol
, vol.70
, pp. 331-338
-
-
Yoshimoto, M.1
Takao, S.2
Hirata, M.3
-
64
-
-
83255191654
-
Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer
-
21775129 1:CAS:528:DC%2BC3MXhsF2ru7nJ 10.1016/j.ejca.2011.06.040
-
Fedele P, Marino A, Orlando L et al (2012) Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer 48:24-29
-
(2012)
Eur J Cancer
, vol.48
, pp. 24-29
-
-
Fedele, P.1
Marino, A.2
Orlando, L.3
-
65
-
-
0034126765
-
Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: A phase II study
-
10856097 1:CAS:528:DC%2BD3cXkvFWrsLc%3D
-
Smith IE, Johnston SR, O'Brien ME et al (2000) Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study. J Clin Oncol 18:2378-2384
-
(2000)
J Clin Oncol
, vol.18
, pp. 2378-2384
-
-
Smith, I.E.1
Johnston, S.R.2
O'Brien, M.E.3
-
66
-
-
84859478512
-
Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer
-
22514500 1:STN:280:DC%2BC38rmtFyktQ%3D%3D 10.3747/co.19.879
-
Young SD, Lafrenie RM, Clemons MJ (2012) Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer. Curr Oncol 19:e75-e78
-
(2012)
Curr Oncol
, vol.19
-
-
Young, S.D.1
Lafrenie, R.M.2
Clemons, M.J.3
-
67
-
-
77955616240
-
Low dose metronomic oral administration of vinorelbine in the first line treatment of elderly patients with metastatic breast cancer
-
10.3816/CBC.2010.n.039 1:CAS:528:DC%2BC3cXhtFSnurjL
-
Addeo R, Sgambato A, Cennamo G et al (2010) Low dose metronomic oral administration of vinorelbine in the first line treatment of elderly patients with metastatic breast cancer. Clinical Breast Cancer 4:301-306
-
(2010)
Clinical Breast Cancer
, vol.4
, pp. 301-306
-
-
Addeo, R.1
Sgambato, A.2
Cennamo, G.3
-
68
-
-
78650253350
-
Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate
-
20566427 1:CAS:528:DC%2BC3MXkvVynurs%3D
-
Licchetta A, Correale P, Migali C et al (2010) Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate. J Chemother 22:201-204
-
(2010)
J Chemother
, vol.22
, pp. 201-204
-
-
Licchetta, A.1
Correale, P.2
Migali, C.3
-
69
-
-
33747032320
-
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients
-
16877730 1:CAS:528:DC%2BD28XovVSjsLk%3D 10.1200/JCO.2005.04.5773
-
Bottini A, Generali D, Brizzi MP et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24:3623-3628
-
(2006)
J Clin Oncol
, vol.24
, pp. 3623-3628
-
-
Bottini, A.1
Generali, D.2
Brizzi, M.P.3
-
70
-
-
54449099774
-
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
-
18794539 1:CAS:528:DC%2BD1cXhtlGitrzI 10.1200/JCO.2008.17.4789
-
Dellapasqua S, Bertolini F, Bagnardi V et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26:4899-4905
-
(2008)
J Clin Oncol
, vol.26
, pp. 4899-4905
-
-
Dellapasqua, S.1
Bertolini, F.2
Bagnardi, V.3
-
71
-
-
84861111904
-
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: Clinical and biological activity
-
22520733 1:CAS:528:DC%2BC38XntlShtro%3D 10.1016/j.clbc.2012.03.008
-
Montagna E, Cancello G, Bagnardi V et al (2012) Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. Clin Breast Cancer 12:207-214
-
(2012)
Clin Breast Cancer
, vol.12
, pp. 207-214
-
-
Montagna, E.1
Cancello, G.2
Bagnardi, V.3
-
72
-
-
57049164414
-
Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane refractory breast cancer
-
19028628 1:CAS:528:DC%2BD1cXhsFemsLvI
-
Garcia-Saenz JA, Martin M, Calles A et al (2008) Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane refractory breast cancer. J Chemother 20:632-639
-
(2008)
J Chemother
, vol.20
, pp. 632-639
-
-
Garcia-Saenz, J.A.1
Martin, M.2
Calles, A.3
-
73
-
-
79960284087
-
Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer
-
21766488 1:STN:280:DC%2BC3MnovVGmsg%3D%3D
-
Saloustros E, Kalbakis K, Vardakis N et al (2011) Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. J Buon 16:215-218
-
(2011)
J Buon
, vol.16
, pp. 215-218
-
-
Saloustros, E.1
Kalbakis, K.2
Vardakis, N.3
-
74
-
-
84879798525
-
Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer
-
22295231
-
Soriano JL, Batista N, Santiesteban E et al (2011) Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer. Int J Breast Cancer 2011:710292
-
(2011)
Int J Breast Cancer
, vol.2011
, pp. 710292
-
-
Soriano, J.L.1
Batista, N.2
Santiesteban, E.3
-
75
-
-
63049102784
-
Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National surgical adjuvant study for breast cancer 01 trial
-
19204202 1:CAS:528:DC%2BD1MXksF2iu70%3D 10.1200/JCO.2008.18.3939
-
Watanabe T, Sano M, Takashima S et al (2009) Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: national surgical adjuvant study for breast cancer 01 trial. J Clin Oncol 27:1368-1374
-
(2009)
J Clin Oncol
, vol.27
, pp. 1368-1374
-
-
Watanabe, T.1
Sano, M.2
Takashima, S.3
-
76
-
-
74849108808
-
Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: A pooled analysis of two randomized controlled trials (NSAS-BC 01 trial and CUBC trial)
-
19936917 1:CAS:528:DC%2BC3cXlslWktQ%3D%3D 10.1007/s10549-009-0635-3
-
Ohashi Y, Watanabe T, Sano M et al (2010) Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (NSAS-BC 01 trial and CUBC trial). Breast Cancer Res Treat 119:633-641
-
(2010)
Breast Cancer Res Treat
, vol.119
, pp. 633-641
-
-
Ohashi, Y.1
Watanabe, T.2
Sano, M.3
-
77
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
-
18506025 1:CAS:528:DC%2BD1cXpvVWmtLg%3D 10.1200/JCO.2007.15.0375
-
Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551
-
(2008)
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
Von Pawel, J.3
-
78
-
-
0042413836
-
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group
-
12837811 1:CAS:528:DC%2BD2cXpsVWqt7c%3D 10.1200/JCO.2003.12.046
-
Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016-3024
-
(2003)
J Clin Oncol
, vol.21
, pp. 3016-3024
-
-
Fossella, F.1
Pereira, J.R.2
Von Pawel, J.3
-
79
-
-
65349116059
-
FLEX study TeamCetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial
-
19410716 1:CAS:528:DC%2BD1MXltlaqurs%3D 10.1016/S0140-6736(09)60569-9
-
Pirker R, Pereira JR, Szczesna A et al (2009) FLEX study TeamCetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525-1531
-
(2009)
Lancet
, vol.373
, pp. 1525-1531
-
-
Pirker, R.1
Pereira, J.R.2
Szczesna, A.3
-
80
-
-
69349088824
-
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumour registry of clinical trials
-
19671843 1:CAS:528:DC%2BD1MXpvFeitLs%3D 10.1158/1078-0432.CCR-09-0888
-
Jackman DM, Miller VA, Cioffredi LA et al (2009) Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumour registry of clinical trials. Clin Cancer Res 15:5267-5273
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5267-5273
-
-
Jackman, D.M.1
Miller, V.A.2
Cioffredi, L.A.3
-
81
-
-
22044445517
-
National Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancer
-
16014882 1:CAS:528:DC%2BD2MXmtFaksbo%3D 10.1056/NEJMoa050753
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) National Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
82
-
-
16544369867
-
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
-
15102997 1:CAS:528:DC%2BD2cXjt12mt7c%3D 10.1056/NEJMoa032792
-
Kato H, Ichinose Y, Ohta M et al (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721
-
(2004)
N Engl J Med
, vol.350
, pp. 1713-1721
-
-
Kato, H.1
Ichinose, Y.2
Ohta, M.3
-
83
-
-
33750693021
-
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non small cell lung cancer patients
-
16786136 1:CAS:528:DC%2BD28Xntlans7w%3D
-
Correale P, Cerretani D, Remondo C et al (2006) A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non small cell lung cancer patients. Oncol Rep 16:133-140
-
(2006)
Oncol Rep
, vol.16
, pp. 133-140
-
-
Correale, P.1
Cerretani, D.2
Remondo, C.3
-
84
-
-
77953720221
-
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumour activity in advanced non-small-cell-lung cancer patients
-
20697196 10.4161/cbt.9.9.11441
-
Correale P, Remondo C, Carbone SF et al (2010) Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumour activity in advanced non-small-cell-lung cancer patients. Cancer Biol Ther 9:685-693
-
(2010)
Cancer Biol Ther
, vol.9
, pp. 685-693
-
-
Correale, P.1
Remondo, C.2
Carbone, S.F.3
-
85
-
-
79960388676
-
Phase II trial of Bevacizumab and dose/dense chemotherapy with Cisplatin and metronomic daily oral etoposide in advanced non small cell lung cancer patients
-
21525780 1:CAS:528:DC%2BC38XhsVaqsLk%3D 10.4161/cbt.12.2.15722
-
Correale P, Botta C, Basile A et al (2011) Phase II trial of Bevacizumab and dose/dense chemotherapy with Cisplatin and metronomic daily oral etoposide in advanced non small cell lung cancer patients. Cancer Biol Ther 12:112-118
-
(2011)
Cancer Biol Ther
, vol.12
, pp. 112-118
-
-
Correale, P.1
Botta, C.2
Basile, A.3
-
86
-
-
43949135185
-
A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)
-
18418020
-
Gorn M, Habermann CR, Anige M et al (2008) A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie 31:185-189
-
(2008)
Onkologie
, vol.31
, pp. 185-189
-
-
Gorn, M.1
Habermann, C.R.2
Anige, M.3
-
87
-
-
39749118576
-
Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer
-
17554539 1:CAS:528:DC%2BD1cXitleru7w%3D 10.1007/s00280-007-0526-4
-
Tas F, Duranyildiz D, Soydinc HO et al (2008) Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer. Cancer Chemother Pharmacol 61:721-725
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 721-725
-
-
Tas, F.1
Duranyildiz, D.2
Soydinc, H.O.3
-
88
-
-
79959615397
-
A multicenter phase i trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC
-
20697712 1:CAS:528:DC%2BC3MXmsFGiu7Y%3D 10.1007/s00280-010-1415-9
-
Pallis AG, Chandrinos V, Pavlakou G et al (2011) A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. Cancer Chemother Pharmacol 67:1239-1245
-
(2011)
Cancer Chemother Pharmacol
, vol.67
, pp. 1239-1245
-
-
Pallis, A.G.1
Chandrinos, V.2
Pavlakou, G.3
-
89
-
-
58149378679
-
Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: A phase II study
-
19142045 1:CAS:528:DC%2BD1MXhsFKksLw%3D 10.1159/000192586
-
Kouroussis C, Vamvakas L, Vardakis N et al (2009) Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study. Oncology 76:112-117
-
(2009)
Oncology
, vol.76
, pp. 112-117
-
-
Kouroussis, C.1
Vamvakas, L.2
Vardakis, N.3
-
90
-
-
79958120436
-
A phase II randomized trial of Gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy
-
21415778 10.1097/JTO.0b013e3182121c09
-
Chen YM, Fan WC, Tsai CM et al (2011) A phase II randomized trial of Gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. J Thorac Oncol 6:1110-1116
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1110-1116
-
-
Chen, Y.M.1
Fan, W.C.2
Tsai, C.M.3
-
91
-
-
34447572873
-
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 [corrected]
-
(Erratum in: J Clin Oncol 25:3790)
-
Maki RG, Wathen JK, Patel SR et al (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25:2755-2763 (Erratum in: J Clin Oncol 25:3790)
-
(2007)
J Clin Oncol
, vol.25
, pp. 2755-2763
-
-
Maki, R.G.1
Wathen, J.K.2
Patel, S.R.3
-
92
-
-
26444442333
-
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: A study by the Spanish Group for Research on Sarcomas
-
16134177 1:CAS:528:DC%2BD2MXhtF2nt7rL 10.1002/cncr.21384
-
Garcia del Muro X, Lopez-Pousa A, Martin J et al (2005) A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 104:1706-1712
-
(2005)
Cancer
, vol.104
, pp. 1706-1712
-
-
Garcia Del Muro, X.1
Lopez-Pousa, A.2
Martin, J.3
-
93
-
-
84861098484
-
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial
-
22595799 10.1016/S0140-6736(12)60651-5 1:CAS:528:DC%2BC38Xnt1CltLo%3D
-
van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879-1886
-
(2012)
Lancet
, vol.379
, pp. 1879-1886
-
-
Van Der Graaf, W.T.1
Blay, J.Y.2
Chawla, S.P.3
-
94
-
-
0037862078
-
Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas
-
12820475 1:CAS:528:DC%2BD3sXltlKisL8%3D
-
Hartmann JT, Oechsle K, Mayer F et al (2003) Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 23:1899-1901
-
(2003)
Anticancer Res
, vol.23
, pp. 1899-1901
-
-
Hartmann, J.T.1
Oechsle, K.2
Mayer, F.3
-
95
-
-
0242526860
-
Antiangiogenetic therapy with pioglitazone, rofecoxib and metronomic trofosfamide in patients with advanced malignant vascular tumours
-
14601096 1:CAS:528:DC%2BD3sXps1ars7k%3D 10.1002/cncr.11775
-
Vogt T, Hafner C, Bross K et al (2003) Antiangiogenetic therapy with pioglitazone, rofecoxib and metronomic trofosfamide in patients with advanced malignant vascular tumours. Cancer 98:2251-2256
-
(2003)
Cancer
, vol.98
, pp. 2251-2256
-
-
Vogt, T.1
Hafner, C.2
Bross, K.3
-
96
-
-
7644238341
-
Pioglitazone and Rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma
-
15470711 1:CAS:528:DC%2BD2cXhtVKisbnL 10.1002/cncr.20574
-
Reichle A, Bross K, Vogt T et al (2004) Pioglitazone and Rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 101:2247-2256
-
(2004)
Cancer
, vol.101
, pp. 2247-2256
-
-
Reichle, A.1
Bross, K.2
Vogt, T.3
-
97
-
-
70350212970
-
Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer
-
19808873 1:CAS:528:DC%2BD1MXhtlyqsbzP 10.1158/1078-0432.CCR-09-0970
-
Briasoulis E, Pappas P, Puozzo C et al (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15:6454-6461
-
(2009)
Clin Cancer Res
, vol.15
, pp. 6454-6461
-
-
Briasoulis, E.1
Pappas, P.2
Puozzo, C.3
-
98
-
-
77951907856
-
Metronomic chemotherapy in advanced soft tissue sarcomas
-
20182726 1:CAS:528:DC%2BC3cXkslalurs%3D 10.1007/s00280-010-1275-3
-
Italiano A, Toulmonde M, Lortal B et al (2010) Metronomic chemotherapy in advanced soft tissue sarcomas. Cancer Chemother Pharmacol 66:197-202
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, pp. 197-202
-
-
Italiano, A.1
Toulmonde, M.2
Lortal, B.3
-
99
-
-
79851508021
-
Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperabile or metastatic soft tissue sarcoma
-
21251814 1:CAS:528:DC%2BC3MXhvVyltLg%3D 10.1016/j.ejca.2010.11.025
-
Mir O, Domont J, Cioffi A et al (2011) Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperabile or metastatic soft tissue sarcoma. Eur J Cancer 47:515-519
-
(2011)
Eur J Cancer
, vol.47
, pp. 515-519
-
-
Mir, O.1
Domont, J.2
Cioffi, A.3
-
100
-
-
4844220366
-
Vinorelbin and low dose cyclophosphamide in the treatment of pediatric sarcomas: Pilot study for upcoming European Rhabdomyosarcoma Protocol
-
15378498 1:CAS:528:DC%2BD2cXovFWhtbY%3D 10.1002/cncr.20544
-
Casanova M, Ferrari A, Bisogno G et al (2004) Vinorelbin and low dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for upcoming European Rhabdomyosarcoma Protocol. Cancer 101:1664-1671
-
(2004)
Cancer
, vol.101
, pp. 1664-1671
-
-
Casanova, M.1
Ferrari, A.2
Bisogno, G.3
-
101
-
-
84866734818
-
Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma-a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE)
-
22633624 1:CAS:528:DC%2BC38Xnsl2qsLY%3D 10.1016/j.ejca.2012.04.012
-
Minard-Colin V, Ichante JL, Nguyen L et al (2012) Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma-a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). Eur J Cancer 48:2409-2416
-
(2012)
Eur J Cancer
, vol.48
, pp. 2409-2416
-
-
Minard-Colin, V.1
Ichante, J.L.2
Nguyen, L.3
-
102
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
20525992 1:CAS:528:DC%2BC3cXhtVCrtrbN 10.1056/NEJMoa1003466
-
Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
103
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
21639810 1:CAS:528:DC%2BC3MXosVegtro%3D 10.1056/NEJMoa1104621
-
Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526
-
(2011)
N Engl J Med
, vol.364
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
-
104
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
21639808 1:CAS:528:DC%2BC3MXosVeitbs%3D 10.1056/NEJMoa1103782
-
Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
105
-
-
77956060635
-
Oral metronomic cyclophosphamide in elderly with metastatic melanoma
-
19669699 1:CAS:528:DC%2BC3cXoslymtr8%3D 10.1007/s10637-009-9298-5
-
Borne E, Desmedt E, Duhamel A et al (2010) Oral metronomic cyclophosphamide in elderly with metastatic melanoma. Invest New Drugs 28:684-689
-
(2010)
Invest New Drugs
, vol.28
, pp. 684-689
-
-
Borne, E.1
Desmedt, E.2
Duhamel, A.3
-
106
-
-
0242329662
-
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: A pilot study
-
12879280 1:CAS:528:DC%2BD3sXotFWmtLs%3D 10.1007/s00280-003-0678-9
-
Spieth K, Kaufmann R, Gille J (2003) Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 52:377-382
-
(2003)
Cancer Chemother Pharmacol
, vol.52
, pp. 377-382
-
-
Spieth, K.1
Kaufmann, R.2
Gille, J.3
-
107
-
-
0141688331
-
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma
-
12947072 1:CAS:528:DC%2BD2cXps1akurc%3D 10.1200/JCO.2003.02.061
-
Hwu WJ, Krown SE, Menell JH et al (2003) Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21:3351-3356
-
(2003)
J Clin Oncol
, vol.21
, pp. 3351-3356
-
-
Hwu, W.J.1
Krown, S.E.2
Menell, J.H.3
-
108
-
-
75649095671
-
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508
-
19918923 1:CAS:528:DC%2BC3cXitFGit7Y%3D 10.1002/cncr.24739
-
Clark JI, Moon J, Hutchins LF et al (2010) Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 116:424-431
-
(2010)
Cancer
, vol.116
, pp. 424-431
-
-
Clark, J.I.1
Moon, J.2
Hutchins, L.F.3
-
109
-
-
77950243302
-
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma
-
20120033 1:CAS:528:DC%2BC3cXkvFOns7s%3D 10.1002/cncr.24902
-
Bhatt RS, Merchan J, Parker R et al (2010) A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer 116:1751-1756
-
(2010)
Cancer
, vol.116
, pp. 1751-1756
-
-
Bhatt, R.S.1
Merchan, J.2
Parker, R.3
-
110
-
-
36048987307
-
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: A randomized phase II trial
-
17992118 1:CAS:528:DC%2BD2sXht1OksLrP 10.1097/CMR.0b013e3282f1d2c8
-
Reichle A, Vogt T, Coras B et al (2007) Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 17:360-364
-
(2007)
Melanoma Res
, vol.17
, pp. 360-364
-
-
Reichle, A.1
Vogt, T.2
Coras, B.3
-
111
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
18650514 1:CAS:528:DC%2BD1cXovFWjsL8%3D 10.1056/NEJMoa0708857
-
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
112
-
-
77953124105
-
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
-
20416968 1:CAS:528:DC%2BC3cXntlajtr0%3D 10.1016/j.jhep.2010.01.035
-
Hsu CH, Shen YC, Lin ZZ et al (2010) Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 53:126-131
-
(2010)
J Hepatol
, vol.53
, pp. 126-131
-
-
Hsu, C.H.1
Shen, Y.C.2
Lin, Z.Z.3
-
113
-
-
84862824694
-
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
-
22310088 1:CAS:528:DC%2BC38XivVCksL8%3D 10.1159/000336126
-
Shao YY, Lin ZZ, Hsu C et al (2012) Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology 82:59-66
-
(2012)
Oncology
, vol.82
, pp. 59-66
-
-
Shao, Y.Y.1
Lin, Z.Z.2
Hsu, C.3
-
114
-
-
65749115668
-
Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer
-
1:CAS:528:DC%2BD1cXhsFejtbnN 10.1007/s00432-008-0443-x
-
Treiber G, Wex T, Malfertheiner P (2009) Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. Cancer Res Clin Oncol 135:271-281
-
(2009)
Cancer Res Clin Oncol
, vol.135
, pp. 271-281
-
-
Treiber, G.1
Wex, T.2
Malfertheiner, P.3
-
115
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumour KRAS and BRAF mutation status
-
21502544 10.1200/JCO.2010.33.5091 1:CAS:528:DC%2BC3MXosF2kur0%3D
-
Van Cutsem E, Köhne CH, Láng I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumour KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E.1
Köhne, C.H.2
Láng, I.3
-
116
-
-
36148941301
-
Cetuximab for the treatment of colorectal cancer
-
18003960 1:CAS:528:DC%2BD2sXhtlWis7rI 10.1056/NEJMoa071834
-
Jonker DJ, O'Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048
-
(2007)
N Engl J Med
, vol.357
, pp. 2040-2048
-
-
Jonker, D.J.1
O'Callaghan, C.J.2
Karapetis, C.S.3
-
117
-
-
42149186928
-
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
-
18362940 1:CAS:528:DC%2BD1cXks12gurg%3D 10.1038/sj.bjc.6604311
-
Allegrini G, Falcone A, Fioravanti A et al (2008) A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 98:1312-1319
-
(2008)
Br J Cancer
, vol.98
, pp. 1312-1319
-
-
Allegrini, G.1
Falcone, A.2
Fioravanti, A.3
-
118
-
-
37049024769
-
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumour patients-results of a phase II study
-
18063875 1:CAS:528:DC%2BD2sXhtlylu7zJ 10.1159/000110580
-
Steinbild S, Arends J, Medinger M et al (2007) Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumour patients-results of a phase II study. Onkologie 30:629-635
-
(2007)
Onkologie
, vol.30
, pp. 629-635
-
-
Steinbild, S.1
Arends, J.2
Medinger, M.3
-
119
-
-
33744799963
-
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumours
-
16707607 1:CAS:528:DC%2BD28Xks1Citb0%3D 10.1158/1078-0432.CCR-05-2255
-
Young SD, Whissell M, Noble JC et al (2006) Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumours. Clin Cancer Res 12:3092-3098
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3092-3098
-
-
Young, S.D.1
Whissell, M.2
Noble, J.C.3
-
120
-
-
84865111710
-
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
-
22382585 1:CAS:528:DC%2BC38XnsVKrt7o%3D 10.1007/s10456-012-9260-6
-
Allegrini G, Di Desidero T, Barletta MT et al (2012) Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15:275-286
-
(2012)
Angiogenesis
, vol.15
, pp. 275-286
-
-
Allegrini, G.1
Di Desidero, T.2
Barletta, M.T.3
-
121
-
-
34547824591
-
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma
-
17695422 1:CAS:528:DC%2BD2sXpvFChsbw%3D
-
Ogata Y, Sasatomi T, Mori S et al (2007) Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma. Anticancer Res 27:2605-2611
-
(2007)
Anticancer Res
, vol.27
, pp. 2605-2611
-
-
Ogata, Y.1
Sasatomi, T.2
Mori, S.3
-
122
-
-
34250637586
-
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer
-
17111120 1:CAS:528:DC%2BD2sXmsVOjsrg%3D 10.1007/s00280-006-0377-4
-
Lin PC, Chen WS, Chao TC et al (2007) Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol 60:351-356
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 351-356
-
-
Lin, P.C.1
Chen, W.S.2
Chao, T.C.3
-
123
-
-
38549129734
-
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence
-
18365541 1:CAS:528:DC%2BD1cXitFSiur4%3D
-
Ogata Y, Mori S, Ishibashi N et al (2007) Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence. J Exp Clin Cancer Res 26:475-482
-
(2007)
J Exp Clin Cancer Res
, vol.26
, pp. 475-482
-
-
Ogata, Y.1
Mori, S.2
Ishibashi, N.3
-
124
-
-
0028959887
-
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
-
7533517 10.1038/bjc.1995.114
-
Pyrhönen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
-
(1995)
Br J Cancer
, vol.71
, pp. 587-591
-
-
Pyrhönen, S.1
Kuitunen, T.2
Nyandoto, P.3
-
125
-
-
80054747516
-
Metronomic docetaxel chemotherapy inhibits angiogenesis and tumour growth in a gastric cancer model
-
21290245 1:CAS:528:DC%2BC3MXht1eiu77F 10.1007/s00280-011-1563-6
-
Wu H, Xin Y, Zhao J et al (2011) Metronomic docetaxel chemotherapy inhibits angiogenesis and tumour growth in a gastric cancer model. Cancer Chemother Pharmacol 68:879-887
-
(2011)
Cancer Chemother Pharmacol
, vol.68
, pp. 879-887
-
-
Wu, H.1
Xin, Y.2
Zhao, J.3
-
126
-
-
52149087173
-
Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo
-
18708754 1:CAS:528:DC%2BD1cXhsVKms7zJ 10.4161/cbt.7.9.6416
-
Cejka D, Preusser M, Woehrer A et al (2008) Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 7:1377-1385
-
(2008)
Cancer Biol Ther
, vol.7
, pp. 1377-1385
-
-
Cejka, D.1
Preusser, M.2
Woehrer, A.3
-
127
-
-
84864037592
-
Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy
-
He S, Shen J, Hong L, Niu L (2011) Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol 9:100-106
-
(2011)
Med Oncol
, vol.9
, pp. 100-106
-
-
He, S.1
Shen, J.2
Hong, L.3
Niu, L.4
-
128
-
-
70749123821
-
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network
-
19886987 10.1186/1471-2407-9-388 1:CAS:528:DC%2BD1MXhsVSjurjJ
-
Brizzi MP, Berruti A, Ferrero A et al (2009) Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 9:388
-
(2009)
BMC Cancer
, vol.9
, pp. 388
-
-
Brizzi, M.P.1
Berruti, A.2
Ferrero, A.3
-
129
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
15470214 1:CAS:528:DC%2BD2cXot1Kmu7c%3D 10.1056/NEJMoa041318
-
Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
-
(2004)
N Engl J Med
, vol.351
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
-
130
-
-
38349167518
-
Docetaxel plus prednisone or Mitoxantrone plus prednisoefor advanced prostate cancer: Updated survival in the TAX 327 study
-
18182665 1:CAS:528:DC%2BD1cXitVWitLs%3D 10.1200/JCO.2007.12.4008
-
Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or Mitoxantrone plus prednisoefor advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242-245
-
(2008)
J Clin Oncol
, vol.26
, pp. 242-245
-
-
Berthold, D.R.1
Pond, G.R.2
Soban, F.3
-
131
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial
-
20888992 10.1016/S0140-6736(10)61389-X 1:CAS:528:DC%2BC3cXht1ersr%2FJ
-
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147-1154
-
(2010)
Lancet
, vol.376
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
132
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
21612468 10.1056/NEJMoa1014618
-
de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
-
(2011)
N Engl J Med
, vol.364
, pp. 1995-2005
-
-
De Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
133
-
-
34248190133
-
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: A phase II study
-
17509300 1:CAS:528:DC%2BD2sXmslKlu78%3D 10.1016/j.juro.2007.01.143
-
Lord R, Nair S, Schache A et al (2007) Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177:2136-2140
-
(2007)
J Urol
, vol.177
, pp. 2136-2140
-
-
Lord, R.1
Nair, S.2
Schache, A.3
-
134
-
-
0141958313
-
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
-
14534880 1:CAS:528:DC%2BD3sXovVCrs7s%3D 10.1002/cncr.11713
-
Glode LM, Barqawi A, Crighton F et al (2003) Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 98:1643-1648
-
(2003)
Cancer
, vol.98
, pp. 1643-1648
-
-
Glode, L.M.1
Barqawi, A.2
Crighton, F.3
-
135
-
-
77956363740
-
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy
-
19365737 1:CAS:528:DC%2BC3cXlsVSqtro%3D 10.1007/s12032-009-9218-8
-
Nelius T, Klatte T, De Reise W et al (2010) Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol 27:363-367
-
(2010)
Med Oncol
, vol.27
, pp. 363-367
-
-
Nelius, T.1
Klatte, T.2
De Reise, W.3
-
136
-
-
78650253824
-
Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure
-
21036758 1:CAS:528:DC%2BC3MXktF2n
-
Ladoire S, Eymard JC, Zanetta S et al (2010) Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. Anticancer Res 30:4317-4323
-
(2010)
Anticancer Res
, vol.30
, pp. 4317-4323
-
-
Ladoire, S.1
Eymard, J.C.2
Zanetta, S.3
-
137
-
-
68049137904
-
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer
-
19622584 1:CAS:528:DC%2BD1MXptl2gtr8%3D 10.1158/1078-0432.CCR-08-3317
-
Fontana A, Galli L, Fioravanti A et al (2009) Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 15:4954-4962
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4954-4962
-
-
Fontana, A.1
Galli, L.2
Fioravanti, A.3
-
138
-
-
17744367405
-
Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer
-
11150908 1:STN:280:DC%2BD3M7hvVShuw%3D%3D 10.1159/000055296
-
Nishimura K, Nonomura N, Ono Y et al (2001) Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology 60:49-54
-
(2001)
Oncology
, vol.60
, pp. 49-54
-
-
Nishimura, K.1
Nonomura, N.2
Ono, Y.3
-
139
-
-
80455143255
-
Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel
-
22054386 10.1016/j.urology.2011.08.010
-
Gebbia V, Serretta V, Borsellino N et al (2011) Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel. Urology 78:1125-1130
-
(2011)
Urology
, vol.78
, pp. 1125-1130
-
-
Gebbia, V.1
Serretta, V.2
Borsellino, N.3
-
140
-
-
79251626392
-
Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer
-
21071389 10.1093/jjco/hyq178
-
Hatano K, Nonomura N, Nishimura K et al (2011) Retrospective analysis of
-
(2011)
Jpn J Clin Oncol
, vol.41
, pp. 253-259
-
-
Hatano, K.1
Nonomura, N.2
Nishimura, K.3
-
141
-
-
79960999855
-
Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer - Review of the literature
-
21277093 1:CAS:528:DC%2BC3MXpvFGisLc%3D 10.1016/j.ctrv.2010.12.006
-
Nelius T, Rinard K, Filleur S (2011) Oral/metronomic cyclophosphamide- based chemotherapy as option for patients with castration-refractory prostate cancer - review of the literature. Cancer Treat Rev 37:444-455
-
(2011)
Cancer Treat Rev
, vol.37
, pp. 444-455
-
-
Nelius, T.1
Rinard, K.2
Filleur, S.3
-
142
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
17215529 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 10.1056/NEJMoa065044
-
Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
143
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
20100962 1:CAS:528:DC%2BC3cXktF2lt78%3D 10.1200/JCO.2009.23.9764
-
Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061-1068
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
-
144
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
17215530 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 10.1056/NEJMoa060655
-
Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
145
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
18653228 1:CAS:528:DC%2BD1cXps1GmsLY%3D 10.1016/S0140-6736(08)61039-9
-
Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
146
-
-
82755183572
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
-
22056247 1:CAS:528:DC%2BC3MXhsFGqsL%2FP 10.1016/S0140-6736(11)61613-9
-
Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931-1939
-
(2011)
Lancet
, vol.378
, pp. 1931-1939
-
-
Rini, B.I.1
Escudier, B.2
Tomczak, P.3
-
147
-
-
0033980850
-
Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
-
10732751 1:CAS:528:DC%2BD3cXhs1yht7Y%3D 10.1054/bjoc.1999.1004
-
Eisen T, Boshoff C, Mak I et al (2000) Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82:812-817
-
(2000)
Br J Cancer
, vol.82
, pp. 812-817
-
-
Eisen, T.1
Boshoff, C.2
Mak, I.3
-
148
-
-
34247383919
-
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma
-
17009033 1:CAS:528:DC%2BD2sXksVOgsLg%3D 10.1007/s00280-006-0347-x
-
Krzyzanowska MK, Tannock IF, Lockwood G et al (2007) A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol 60:135-141
-
(2007)
Cancer Chemother Pharmacol
, vol.60
, pp. 135-141
-
-
Krzyzanowska, M.K.1
Tannock, I.F.2
Lockwood, G.3
-
149
-
-
84866303137
-
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: Final results of a prospective phase II trial
-
21607771 10.1007/s12032-011-9982-0 1:CAS:528:DC%2BC38XmsF2gsL0%3D
-
Walter B, Schrettenbrunner I, Vogelhuber M et al (2011) Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. Med Oncol 29:799-805
-
(2011)
Med Oncol
, vol.29
, pp. 799-805
-
-
Walter, B.1
Schrettenbrunner, I.2
Vogelhuber, M.3
-
150
-
-
77950312919
-
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (SOGUG-02-06)
-
20163987 1:CAS:528:DC%2BC3cXjvF2nu78%3D 10.1016/S1470-2045(09)70383-3
-
Bellmunt J, Trigo JM, Calvo E et al (2010) Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 11:350-357
-
(2010)
Lancet Oncol
, vol.11
, pp. 350-357
-
-
Bellmunt, J.1
Trigo, J.M.2
Calvo, E.3
-
151
-
-
84855425106
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer
-
22204724 1:CAS:528:DC%2BC38XktVWhsg%3D%3D 10.1056/NEJMoa1104390
-
Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483
-
(2011)
N Engl J Med
, vol.365
, pp. 2473-2483
-
-
Burger, R.A.1
Brady, M.F.2
Bookman, M.A.3
-
152
-
-
79961139784
-
Management strategies for recurrent platinum-resistant ovarian cancer
-
21812505 1:CAS:528:DC%2BC3MXht1GmtrfE 10.2165/11591720-000000000-00000
-
Naumann RW, Coleman RL (2011) Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71:1397-1412
-
(2011)
Drugs
, vol.71
, pp. 1397-1412
-
-
Naumann, R.W.1
Coleman, R.L.2
-
153
-
-
35348904080
-
Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
-
17706754 1:CAS:528:DC%2BD2sXhtF2iurjK 10.1016/j.ygyno.2007.07.017
-
Chura JC, Van Iseghem K, Downs LS et al (2007) Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 107:326-330
-
(2007)
Gynecol Oncol
, vol.107
, pp. 326-330
-
-
Chura, J.C.1
Van Iseghem, K.2
Downs, L.S.3
-
154
-
-
78149433404
-
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
-
21079407 1:CAS:528:DC%2BC3MXhtlaktA%3D%3D 10.1159/000320602
-
Sanchez-Munoz A, Mendiola C, Perez-Ruiz E et al (2010) Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology 79:98-100
-
(2010)
Oncology
, vol.79
, pp. 98-100
-
-
Sanchez-Munoz, A.1
Mendiola, C.2
Perez-Ruiz, E.3
-
155
-
-
37849035249
-
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II Consortia
-
18165643 1:CAS:528:DC%2BD1cXhsVCrsLc%3D 10.1200/JCO.2007.12.1939
-
Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II Consortia. J Clin Oncol 26:76-82
-
(2008)
J Clin Oncol
, vol.26
, pp. 76-82
-
-
Garcia, A.A.1
Hirte, H.2
Fleming, G.3
-
156
-
-
80053634371
-
Use of metronomic chemotherapy in oncology: Results from a national Italian survey
-
21989433
-
Collovà E et al (2011) Use of metronomic chemotherapy in oncology: results from a national Italian survey. Tumori 97:454-458
-
(2011)
Tumori
, vol.97
, pp. 454-458
-
-
Collovà, E.1
-
157
-
-
27644436870
-
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
-
15998832 1:CAS:528:DC%2BD2MXht1WntrzO 10.1182/blood-2005-04-1422
-
Shaked Y, Emmenegger U, Man S et al (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106:3058-3061
-
(2005)
Blood
, vol.106
, pp. 3058-3061
-
-
Shaked, Y.1
Emmenegger, U.2
Man, S.3
-
158
-
-
33847368549
-
Metronomic cyclophosphamide regimen selectively depletesCD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients
-
16960692 1:CAS:528:DC%2BD2sXisVaqtbY%3D 10.1007/s00262-006-0225-8
-
Ghiringhelli F, Menard C, Puig PE et al (2007) Metronomic cyclophosphamide regimen selectively depletesCD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641-648
-
(2007)
Cancer Immunol Immunother
, vol.56
, pp. 641-648
-
-
Ghiringhelli, F.1
Menard, C.2
Puig, P.E.3
-
159
-
-
68549112974
-
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
-
19221744 1:CAS:528:DC%2BD1MXptVensbY%3D 10.1007/s00262-009-0671-1
-
Banissi C, Ghiringhelli F, Chen L, Carpentier AF (2009) Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 58:1627-1634
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 1627-1634
-
-
Banissi, C.1
Ghiringhelli, F.2
Chen, L.3
Carpentier, A.F.4
-
160
-
-
61349201682
-
Immunomodulation of FOXP3 + regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients
-
19188178 1:CAS:528:DC%2BD1MXht1Onsrg%3D 10.1158/1078-0432.CCR-08-1507
-
Generali D, Bates G, Berruti A et al (2009) Immunomodulation of FOXP3 + regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 15:1046-1051
-
(2009)
Clin Cancer Res
, vol.15
, pp. 1046-1051
-
-
Generali, D.1
Bates, G.2
Berruti, A.3
-
161
-
-
3142767799
-
Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas
-
15254283 1:CAS:528:DC%2BD2cXlslKrurg%3D 10.1056/NEJMoa033153
-
Streubel B, Chott A, Huber D et al (2004) Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351:250-259
-
(2004)
N Engl J Med
, vol.351
, pp. 250-259
-
-
Streubel, B.1
Chott, A.2
Huber, D.3
-
162
-
-
33644770150
-
Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion
-
16317105 1:CAS:528:DC%2BD28XisFOju7s%3D 10.1182/blood-2005-04-1768
-
Rigolin GM, Fraulini C, Ciccone M et al (2006) Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 107:2531-2535
-
(2006)
Blood
, vol.107
, pp. 2531-2535
-
-
Rigolin, G.M.1
Fraulini, C.2
Ciccone, M.3
-
163
-
-
84857197449
-
Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment
-
22245726 1:CAS:528:DC%2BC38XksFaqtbc%3D 10.1016/j.ajpath.2011.11.029
-
Akiyama K, Ohga N, Hida Y et al (2012) Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol 180:1283-1293
-
(2012)
Am J Pathol
, vol.180
, pp. 1283-1293
-
-
Akiyama, K.1
Ohga, N.2
Hida, Y.3
-
164
-
-
84879501946
-
Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells
-
(Epub ahead of print)
-
Pasquier E, Tuset MP, Street J et al (2012) Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis (Epub ahead of print)
-
(2012)
Angiogenesis
-
-
Pasquier, E.1
Tuset, M.P.2
Street, J.3
-
165
-
-
0041589524
-
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
-
12907602 1:CAS:528:DC%2BD3sXmtFekurY%3D
-
Bertolini F, Paul S, Mancuso P et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346
-
(2003)
Cancer Res
, vol.63
, pp. 4342-4346
-
-
Bertolini, F.1
Paul, S.2
Mancuso, P.3
-
166
-
-
84859395499
-
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumour effects in the absence of inhibition of systemic vasculogenesis
-
22188817 1:CAS:528:DC%2BC38XjtlKis74%3D 10.1158/1535-7163.MCT-11-0659
-
Francia G, Shaked Y, Hashimoto K et al (2012) Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumour effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther 11:680-689
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 680-689
-
-
Francia, G.1
Shaked, Y.2
Hashimoto, K.3
-
167
-
-
0037728892
-
Repopulation in murine breast tumours during and after sequential treatments with cyclophosphamide and 5-fluorouracil
-
12727830 1:CAS:528:DC%2BD3sXjtlGmtr8%3D
-
Wu L, Tannock I (2003) Repopulation in murine breast tumours during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res 63:2134-2138
-
(2003)
Cancer Res
, vol.63
, pp. 2134-2138
-
-
Wu, L.1
Tannock, I.2
-
168
-
-
73649149422
-
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents
-
20068365 1:CAS:528:DC%2BC3cXit1OntrY%3D 10.1159/000275830
-
Noberasco C, Spitaleri G, Mancuso P et al (2009) Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. Oncology 77:358-365
-
(2009)
Oncology
, vol.77
, pp. 358-365
-
-
Noberasco, C.1
Spitaleri, G.2
Mancuso, P.3
-
169
-
-
80053557082
-
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
-
21986371 1:CAS:528:DC%2BC3MXhtlKrtbrL 10.1159/000331684
-
Shao YY, Lin ZZ, Chen TJ et al (2011) High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. Oncology 81:98-103
-
(2011)
Oncology
, vol.81
, pp. 98-103
-
-
Shao, Y.Y.1
Lin, Z.Z.2
Chen, T.J.3
-
170
-
-
78649465366
-
Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate postresistance therapy
-
20685298 1:CAS:528:DC%2BC3cXhsVyhur3P
-
Bertolini F, Marighetti P, Shaked Y (2010) Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. Biochim Biophys Acta 1806:131-137
-
(2010)
Biochim Biophys Acta
, vol.1806
, pp. 131-137
-
-
Bertolini, F.1
Marighetti, P.2
Shaked, Y.3
-
171
-
-
73349127099
-
Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab
-
19996223 1:CAS:528:DC%2BD1MXhsFGgurvE 10.1158/1078-0432.CCR-09-1493
-
Calleri A, Bono A, Bagnardi V et al (2009) Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15:7652-7657
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7652-7657
-
-
Calleri, A.1
Bono, A.2
Bagnardi, V.3
-
172
-
-
37849008812
-
Biologic markers of angiogenesis: Circulating endothelial cells in patients with advanced malignancies treated on phase i protocol with metronomic chemotherapy and celecoxib
-
18181046 1:CAS:528:DC%2BD1cXisFOksA%3D%3D 10.1080/07357900701681541
-
Twardowski PW, Smith-Powell L, Carroll M et al (2008) Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest 26:53-59
-
(2008)
Cancer Invest
, vol.26
, pp. 53-59
-
-
Twardowski, P.W.1
Smith-Powell, L.2
Carroll, M.3
-
173
-
-
0242331613
-
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
-
14561896 1:CAS:528:DC%2BD3sXoslKnu7g%3D 10.1073/pnas.2135406100
-
Bocci G, Francia G, Man S et al (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 100:12917-12922
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 12917-12922
-
-
Bocci, G.1
Francia, G.2
Man, S.3
-
174
-
-
28144453993
-
Feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer
-
16282886 10.1097/01.mph.0000183863.10792.d4
-
Kieran MW, Turner CD, Rubin JB et al (2005) Feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27:573-581
-
(2005)
J Pediatr Hematol Oncol
, vol.27
, pp. 573-581
-
-
Kieran, M.W.1
Turner, C.D.2
Rubin, J.B.3
-
175
-
-
84856557454
-
Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy
-
20449626 1:CAS:528:DC%2BC38XotVWjsA%3D%3D 10.1007/s10637-010-9443-1
-
Lansiaux A, Salingue S, Dewitte A et al (2012) Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy. Invest New Drugs 30:403-404
-
(2012)
Invest New Drugs
, vol.30
, pp. 403-404
-
-
Lansiaux, A.1
Salingue, S.2
Dewitte, A.3
-
176
-
-
77950867636
-
Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
-
20354522 1:CAS:528:DC%2BC3cXksFOltr8%3D 10.1038/sj.bjc.6605623
-
Penel N, Clisant S, Dansin E et al (2010) Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. Br J Cancer 102:1207-1212
-
(2010)
Br J Cancer
, vol.102
, pp. 1207-1212
-
-
Penel, N.1
Clisant, S.2
Dansin, E.3
-
177
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
18650835 1:CAS:528:DC%2BD1cXovV2lsrk%3D 10.1038/nrc2442
-
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
178
-
-
0020583997
-
Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division
-
6134736 1:CAS:528:DyaL3sXkvVCksLs%3D 10.1083/jcb.97.1.22
-
Cabral FR (1983) Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol 97:22-29
-
(1983)
J Cell Biol
, vol.97
, pp. 22-29
-
-
Cabral, F.R.1
-
179
-
-
0030931827
-
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
-
9276747 1:CAS:528:DyaK2sXlvFOgtr0%3D 10.1172/JCI119642
-
Kavallaris M, Kuo DY, Burkhart CA et al (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100:1282-1293
-
(1997)
J Clin Invest
, vol.100
, pp. 1282-1293
-
-
Kavallaris, M.1
Kuo, D.Y.2
Burkhart, C.A.3
-
180
-
-
21344471145
-
A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence
-
15956256 1:CAS:528:DC%2BD2MXltFWrtr8%3D 10.1158/1535-7163.MCT-05-0024
-
Yang CP, Verdier-Pinard P, Wang F et al (2005) A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther 4:987-995
-
(2005)
Mol Cancer Ther
, vol.4
, pp. 987-995
-
-
Yang, C.P.1
Verdier-Pinard, P.2
Wang, F.3
-
181
-
-
84860160775
-
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: A multicenter experience
-
22538363 1:CAS:528:DC%2BC38Xnt1aqsbc%3D 10.1159/000336483
-
Zapletalova D, Andre N, Deak L et al (2012) Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology 82:249-260
-
(2012)
Oncology
, vol.82
, pp. 249-260
-
-
Zapletalova, D.1
Andre, N.2
Deak, L.3
-
182
-
-
0036897097
-
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a elective antiangiogenic window for various chemotherapeutic drugs
-
12460910 1:CAS:528:DC%2BD38XpsVahsLg%3D
-
Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a elective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938-6943
-
(2002)
Cancer Res
, vol.62
, pp. 6938-6943
-
-
Bocci, G.1
Nicolaou, K.C.2
Kerbel, R.S.3
-
183
-
-
0037445124
-
Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: A case-control study by the Société Française d'Oncologie Pédiatrique
-
12637473 10.1200/JCO.2003.04.100 1:CAS:528:DC%2BD2cXpsVGqtro%3D
-
Le Deley MC, Leblanc T, Shamsaldin A et al (2003) Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol 21:1074-1081
-
(2003)
J Clin Oncol
, vol.21
, pp. 1074-1081
-
-
Le Deley, M.C.1
Leblanc, T.2
Shamsaldin, A.3
-
184
-
-
85040673800
-
Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: A case report
-
10.1186/1752-1947-4-274
-
Shaikh AJ, Masood N (2010) Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report. J Med Case Reports 4:274
-
(2010)
J Med Case Reports
, vol.4
, pp. 274
-
-
Shaikh, A.J.1
Masood, N.2
|